Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Theravance Biopharma ( (TBPH) ) has issued an announcement.
Theravance Biopharma disclosed that its management will hold one-on-one meetings with analysts and investors in San Francisco from January 12–15, 2026, using a corporate presentation that underscores its transition to a cash-generating biotech with a solid balance sheet and near-term clinical catalysts. The materials highlight that the company reached breakeven in the third quarter of 2025 and expects similar performance in the fourth quarter, supported by strong U.S. profit share from YUPELRI, intellectual property protection on that product into 2039, and about $175 million in anticipated near-term sales-based milestones, while positioning ampreloxetine—now through a completed Phase 3 CYPRESS randomized withdrawal study with topline data expected in the first quarter of 2026—as a potential first-in-class, once-daily treatment for an estimated 40,000 underserved U.S. patients with symptomatic neurogenic orthostatic hypotension due to multiple system atrophy. These developments, combined with an experienced leadership team and a stated commitment to returning excess capital to shareholders, suggest a strengthening operational and financial footing that could enhance Theravance Biopharma’s competitive standing in specialty neurology and respiratory markets.
The most recent analyst rating on (TBPH) stock is a Buy with a $20.50 price target. To see the full list of analyst forecasts on Theravance Biopharma stock, see the TBPH Stock Forecast page.
Spark’s Take on TBPH Stock
According to Spark, TipRanks’ AI Analyst, TBPH is a Neutral.
Theravance Biopharma’s overall stock score reflects a combination of strong earnings call results and technical indicators, alongside moderate financial performance and valuation. The company’s robust cash position and strategic milestones contribute positively, while operational challenges and historical equity fluctuations present risks. The stock’s bullish technical trend and growth-oriented valuation further support the score.
To see Spark’s full report on TBPH stock, click here.
More about Theravance Biopharma
Theravance Biopharma is a commercial-stage biotechnology company focused on respiratory and neurological diseases, with a key marketed product YUPELRI in the U.S. for respiratory patients and an investigational therapy, ampreloxetine, in late-stage development for neurogenic orthostatic hypotension in patients with multiple system atrophy. The company, which has demonstrated an ability to advance in-house assets through approval and commercialization, reported a strong financial position with approximately $333 million in cash, no debt, and cash flow supported by a profit-sharing arrangement on YUPELRI and potential sales-based milestones tied to Trelegy and YUPELRI.
Average Trading Volume: 479,159
Technical Sentiment Signal: Buy
Current Market Cap: $963.8M
See more insights into TBPH stock on TipRanks’ Stock Analysis page.